other material
confidence high
sentiment positive
materiality 0.60
Genprex granted US patent for REQORSA plus PD-L1 antibody combo through 2037
Genprex, Inc.
- USPTO patent covers REQORSA gene therapy combined with PD-L1 antibodies like Tecentriq, securing exclusivity to 2037.
- Patents now granted in US and Korea; applications pending in Europe, Canada, Brazil, China, Israel.
- Acclaim-3 Phase 1/2 trial for ES-SCLC combines REQORSA with Genentech's Tecentriq; Phase 2 expansion to enroll ~50 patients.
- Interim analysis planned after 25th patient reaches 18 weeks; enrollment completion expected first half 2026.
- Acclaim-3 has FDA Fast Track and Orphan Drug designations.